Cipla is reportedly planning to ink marketing pact with Pune-based unlisted Serum Institute. According to the agreement, Cipla will sell Serum’s products in Europe and Africa.
Serum is one of the world’s biggest producers of vaccines and is unlisted. In the last few years, Cipla has strengthened its distribution in Africa by buying a company in South Africa and is planning to raise overseas contribution to its revenues to 80%.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.
